Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Verbrinacogene Setparvovec in Hemophilia B: NCT05164471 Clinical Landscape Report 2026
16 October 2026
NCT05164471 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rentosertib in Idiopathic Pulmonary Fibrosis: NCT05154240 Clinical Landscape Report 2026
16 October 2026
NCT05154240 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trehalose in Neurodegenerative Diseases: ACTRN12621001755820 Clinical Landscape Report 2026
16 October 2026
ACTRN12621001755820 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Apilimod Dimesylate in Amyotrophic Lateral Sclerosis: NCT05163886 Clinical Landscape Report 2026
16 October 2026
NCT05163886 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ASP-8731 in Anemia, Sickle Cell: NCT05167526 Clinical Landscape Report 2026
16 October 2026
NCT05167526 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Curcumin in Metabolic Dysfunction Associated Steatohepatitis: ISRCTN27793187 Clinical Landscape Report 2026
16 October 2026
ISRCTN27793187 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
Treprostinil palmitil in Idiopathic Pulmonary Fibrosis: NCT05176951 Clinical Landscape Report 2026
16 October 2026
NCT05176951 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pociredir in Acute Chest Syndrome: NCT05169580 Clinical Landscape Report 2026
16 October 2026
NCT05169580 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Donaperminogene Seltoplasmid in Amyotrophic Lateral Sclerosis: NCT05176093 Clinical Landscape Report 2026
16 October 2026
NCT05176093 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Orvepitant in Idiopathic Pulmonary Fibrosis: NCT05185089 Clinical Landscape Report 2026
16 October 2026
NCT05185089 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Edaravone in Amyotrophic Lateral Sclerosis: NCT05178810 Clinical Landscape Report 2026
16 October 2026
NCT05178810 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hemophilia A: NCT05181618 Clinical Landscape Report 2026
16 October 2026
NCT05181618 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.